Top

Acta Neurochirurgica

Published in:

01-07-2020 | Glioma | Original Article - Tumor - Glioma

Associations of histological and molecular alterations with invasion of the corpus callosum in gliomas

Authors: Shaoping Shen, Shiyu Feng, Hailong Liu, Jingjing Jiang, Xinguang Yu

Published in: Acta Neurochirurgica | Issue 7/2020

Abstract

Background

Glioma invading the corpus callosum (CC) accounts for approximately 14% of gliomas and is thought to be more aggressive. However, there is still a lack of studies on the pathogenesis and molecular features of this condition. Here, we examined the occurrence association of CC invasion with respect to patients’ clinical, pathological, and genetic characteristics.

Methods

First, a cohort of 331 patients was included, with 86 cases (26%) that were diagnosed with invasion glioma. They were all analyzed for basic clinical and pathological characteristics and four routinely tested glioma molecular markers. Second, 29 pairs of patients who underwent deep sequencing of 68 glioma molecular alterations were selected from both groups for in-depth analysis.

Results

The results of the first part showed that there was no difference between the two groups in terms of the basic factors in univariate analysis, while in multivariate logistic analysis, WHO grade was the risk factor for CC invasion (p = 0.001). The results of the second part showed that the paired groups had different genetic expression profiles, which highlighted glioma invading the CC as a distinct biological entity. PDGFRA mutation (PDGFRAmut) was present in 9 patients with invasive gliomas (31%), but only in one case (3.4%) in the control group (OR 17.331; 95% CI 1.987–151.156).

Conclusion

Our data revealed the clinical, pathological, and genetic characteristics of glioma invading the CC and showed that it may be associated with glioma WHO grade and PDGFRAmut, but not other factors. Thus, the risk signaling pathway may offer potential therapeutic targets for this disease.

Agrawal A (2009) Butterfly glioma of the corpus callosum. J Cancer Res Ther 5:43–45CrossRefPubMed

Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365. https://doi.org/10.1038/35077225 CrossRefPubMed

Bourekas EC, Varakis K, Bruns D, Christoforidis GA, Baujan M, Slone HW, Kehagias D (2002) Lesions of the corpus callosum: MR imaging and differential considerations in adults and children. AJR Am J Roentgenol 179:251–257. https://doi.org/10.2214/ajr.179.1.1790251 CrossRefPubMed

Chaichana KL, Jusue-Torres I, Lemos AM, Gokaslan A, Cabrera-Aldana EE, Ashary A, Olivi A, Quinones-Hinojosa A (2014) The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors? J Neuro-Oncol 120:625–634. https://doi.org/10.1007/s11060-014-1597-9 CrossRef

Chen KT, Wu TW, Chuang CC, Hsu YH, Hsu PW, Huang YC, Lin TK, Chang CN, Lee ST, Wu CT, Tseng CK, Wang CC, Pai PC, Wei KC, Chen PY (2015) Corpus callosum involvement and postoperative outcomes of patients with gliomas. J Neuro-Oncol 124:207–214. https://doi.org/10.1007/s11060-015-1823-0 CrossRef

Dayani F, Young JS, Bonte A, Chang EF, Theodosopoulos P, McDermott MW, Berger MS, Aghi MK (2018) Safety and outcomes of resection of butterfly glioblastoma. Neurosurg Focus 44:E4. https://doi.org/10.3171/2018.3.FOCUS1857 CrossRefPubMed

Dziurzynski K, Blas-Boria D, Suki D, Cahill DP, Prabhu SS, Puduvalli V, Levine N (2012) Butterfly glioblastomas: a retrospective review and qualitative assessment of outcomes. J Neuro-Oncol 109:555–563. https://doi.org/10.1007/s11060-012-0926-0 CrossRef

Lapin DH, Tsoli M, Ziegler DS (2017) Genomic insights into diffuse intrinsic Pontine Glioma. Front Oncol 7:57. https://doi.org/10.3389/fonc.2017.00057 CrossRefPubMedPubMedCentral

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMed

10.

Monaco EA 3rd, Armah HB, Nikiforova MN, Hamilton RL, Engh JA (2011) Grade II oligodendroglioma localized to the corpus callosum. Brain Tumor Pathol 28:305–309. https://doi.org/10.1007/s10014-011-0054-0 CrossRefPubMed

11.

Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29:3999–4006. https://doi.org/10.1200/JCO.2011.35.5677 CrossRefPubMedPubMedCentral

12.

Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG (2010) Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncology 12:520–527. https://doi.org/10.1093/neuonc/nop066 CrossRefPubMedPubMedCentral

13.

Rees JH, Smirniotopoulos JG, Jones RV, Wong K (1996) From the archives of the AFIP - Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics 16:1413–1438. https://doi.org/10.1148/radiographics.16.6.8946545 CrossRefPubMed

14.

Renard D, Castelnovo G, Campello C, Bouly S, Le Floch A, Thouvenot E, Waconge A, Taieb G (2014) An MRI review of acquired corpus callosum lesions. J Neurol Neurosurg Psychiatry 85:1041–1048. https://doi.org/10.1136/jnnp-2013-307072 CrossRefPubMed

15.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146. https://doi.org/10.1007/s00401-014-1370-3 CrossRefPubMed

16.

Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. https://doi.org/10.3171/2011.2.JNS10998 CrossRefPubMed

17.

Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2:494–503; quiz 1 p following 516. https://doi.org/10.1038/ncpneuro0289 CrossRefPubMed

18.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She YH, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362. https://doi.org/10.1038/nature04304 CrossRefPubMed

19.

Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Narita Y, Ichimura K (2015) Revisiting TP53 mutations and immunohistochemistry--a comparative study in 157 diffuse gliomas. Brain Pathol 25:256–265. https://doi.org/10.1111/bpa.12173 CrossRefPubMed

20.

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T (2015) A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer 51:522–532. https://doi.org/10.1016/j.ejca.2014.12.019 CrossRefPubMed

21.

Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451. https://doi.org/10.1007/s00401-013-1156-z CrossRefPubMed

22.

Yalon M, Rood B, MacDonald TJ, McCowage G, Kane R, Constantini S, Packer RJ (2013) A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer 60:71–76. https://doi.org/10.1002/pbc.24142 CrossRefPubMed

Title: Associations of histological and molecular alterations with invasion of the corpus callosum in gliomas
Authors: Shaoping Shen
Shiyu Feng
Hailong Liu
Jingjing Jiang
Xinguang Yu
Publication date: 01-07-2020
Publisher: Springer Vienna
Keywords: Glioma
Glioma
Glioma
Published in: Acta Neurochirurgica / Issue 7/2020
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-020-04376-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Associations of histological and molecular alterations with invasion of the corpus callosum in gliomas

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2020

Ethical triage during the COVID-19 pandemic: a toolkit for neurosurgical resource allocation

Automated pupillometry and the FOUR score — what is the diagnostic benefit in neurointensive care?

Are we forgetting non-COVID-19-related diseases during lockdown?

Chiari I malformation and pregnancy: a comprehensive review of the literature to address common questions and to guide management

Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor—a pilot study

Alternative continuous intracranial pressure-derived cerebrovascular reactivity metrics in traumatic brain injury: a scoping overview